Connect with us

Science & Health

Johns Hopkins University Announces Nation’s First-Ever Psychedelics Research Center

Published

on

A major U.S. university announced on Wednesday that it will be launching the nation’s first center devoted exclusively to researching psychedelic drugs.

Johns Hopkins University said that it received $17 million in private funding to make the facility possible. A team of six researchers and five postdoctoral scientists will conduct studies on a wide range of potential therapeutic uses of psychedelics like psilocybin, including in treatment of opioid addiction, Alzheimer’s disease, depression, anxiety and post-traumatic stress disorder.

The university has already produced cutting-edge research into psychedelics. In 2000, Johns Hopkins researchers were the first in the U.S. to gain federal approval to reinitiate research into the substances in individuals who didn’t have prior experience with psychedelics. The institution has since published 60 peer-reviewed studies on the subject.

“The group’s findings on both the promise and the risks of psilocybin helped create a path forward for its potential medical approval and reclassification from a Schedule I drug, the most restrictive federal government category, to a more appropriate level,” the university said in a press release. “Psilocybin was classified as Schedule I during the Nixon administration, but research over the last decade has shown psilocybin to have low toxicity and abuse potential.”

Roland Griffiths, the center’s director said the its establishment “reflects a new era of research in therapeutics and the mind through studying this unique and remarkable class of pharmacological compounds.”

“In addition to studies on new therapeutics, we plan to investigate creativity and well-being in healthy volunteers that we hope will open up new ways to support human thriving,” he said.

He also said in response to a question from Marijuana Moment that the center is “both completely new and more of the same,” referring to the university’s existing research into psychedelics.

James Potash, director of the Department of Psychiatry and Behavioral Sciences, said he is “thrilled about this magnificent opportunity that has been provided by enlightened private funders.”

“This center will allow our enormously talented faculty to focus extensively on psychedelic research, where their passions lie and where promising new horizons beckon,” he said.

Tim Ferriss, a tech investor who said his more than $2 million contribution to the psychedelics center was the largest investment he’s ever made in a single project, appeared at a press event and discussed how his personal experience witnessing people suffer from mental illnesses motivated him to donate.

“This represents the largest investment to date in psychedelic research, as well as in training the next generation of psychedelic researchers,” Ferriss said. “I sincerely hope this ambitious Johns Hopkins center will inspire others to think big and establish more psychedelic research centers in the U.S. and overseas, as there’s never been a better time to support such important work.”

Ferriss also took a question via Twitter from Marijuana Moment and said that he hopes that “by facilitating this” center, it “paves the way for federal funding [of psychedelics research] within the next five years.”

He added that the center’s innovations could spark further investments in psychedelics research from “brand name foundations” and that the facility will demonstrate to investors that there’s “more reputational opportunity than risk involved.”

Federal reclassification of the substances “is something that I hope for, but it’s not something I can aim for very accurately for myself,” he said, adding that the center “could mark the beginning of an important, exciting and new chapter in psychedelics research.”

WordPress co-founder Matt Mullenweg and TOMS founder Blake Mycoskie also made investments in the center.

“This very substantial level of funding should enable a quantum leap in psychedelic-focused research,” Potash said. “It will accelerate the process of sorting out what works and what doesn’t.”

“Ultimately [the Food and Drug Administration] needs to sift through that data,” the center’s director added, referring to the results of psychedelics research. “I would guess five plus years before approval for a depression indication, but it might become available sooner if some provisions are opened up for compassionate care.”

The announcement is especially timely given the rapid expansion of psychedelics reform efforts in recent months. Denver became the first city in the U.S. to decriminalize psilocybin mushrooms in May, and Oakland’s City Council approved a psilocybin decriminalization measure in June.

Organizers with the groups Decriminalize Nature and the Society for Psychedelic Outreach, Reform and Education say that they are coordinating with activists all across the country to get decriminalization passed, including one effort to enact the policy statewide in California.

In Oregon, an advocacy group will be collecting signatures to legalize psilocybin for medical use, but that measure has faced criticism from reform groups because after a revision, it no longer includes broad decriminalization provisions.

Interest in lifting barriers to research into psychedelics is widespread and reached the congressional level earlier this year when Rep. Alexandria Ocasio-Cortez (D-NY) introduced an amendment to encourage such research. That measure was defeated on the House floor, however.

This story has been updated to add context about psychedelics policy reform efforts.

Oregon Psychedelics Activists Clash Over Changes To Psilocybin Mushroom Ballot Measure

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Science & Health

Legalizing Medical Marijuana Makes People Have More Sex, Study Shows

Published

on

Legalizing medical marijuana appears to encourage people to have more sex, according to a recent study.

“We find that [medical marijuana laws] cause an increase in sexual activity,” researchers from the University of Connecticut and Georgia State University concluded.

That’s not the only related effect, however, as the study also determined that there’s a decrease in the use of contraceptives and an increase in the number of births following the enactment of medical cannabis policies.

To determine how such laws influence how often people have sex, the team of researchers analyzed a large data set that included “detailed questions about sexual activity and substance use” in young people between 1997 and 2011. The survey asked respondents explicitly about past-month marijuana use and sex frequency.

The analysis found a 4.3 percent increase in the “likelihood of having sex once or more in the past month” after a medical cannabis law was enacted and “an increase in sex beginning directly after the law change.”

“The primary change in sexual behavior we observe is increased engagement in sexual activity.”

Additionally, the effect of medical marijuana laws on births translates to a 2 percent increase, or 684 more births per quarter, “for all women of childbearing range.”

“These results provide evidence that marijuana use has a considerable, unintended, and positive effect on birthrates,” the authors wrote in the paper, which was published late last month in the Journal of Health Economics.

When it comes to contraceptives, the researchers highlight that the sensory effects of cannabis “may change attitudes toward sexual risks by making users less concerned about the consequences of intercourse, resulting in decreased contraceptive use.”

Such behavioral changes could explain why birthrates increase when people have access to medical cannabis, despite what the study authors described as physiological effects associated with marijuana use that could decrease fertility.

“Our findings on births suggest that behavioral factors can counteract the physiological changes from marijuana use that tend to decrease fertility,” they wrote.

“We find that passage of [medical marijuana laws] result in both increased engagement in sexual activity and decreases in contraceptive use conditional on being sexually active,” the study concludes. “Jointly, both mechanisms suggest that behavioral responses may be due to increased attention to the immediate hedonic effects of sexual contact, increased willingness to engage in sex, as well as delayed discounting and ignoring the future costs associated with sex.”

While this study aims to describe behavioral changes in sexual activity after a medical marijuana law is in place, recent research also points to cannabis’s ability to intensify sexual pleasure and increase sex drive for both men and women.

Marijuana Use Before Sex Leads To More Satisfying Orgasms, Study Finds

Photo courtesy of Aphiwat chuangchoem.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Science & Health

People Visiting Safe Injection Sites Are Less Likely To Die Compared To Other Drug Consumers, Study Finds

Published

on

As a growing number of Democratic presidential contenders are voicing support for harm reduction programs such as supervised injection facilities (SIFs), a recent study shows that these candidates are on the right track if they’re really interested in helping save the lives of people who use currently illegal drugs.

Researchers in British Columbia, Canada, found that people “who reported using supervised injection facilities on an at least weekly basis had a reduced risk of dying compared to those who reported less than weekly or no use of this health service.”

Previous studies have shown that safe injection sites help reduce overdose deaths. However, there are only approximately 140 legally operating sites in the world, including in Canada, Australia and Europe. To date, no SIFs have legal approval to operate in the U.S., though some cities are exploring allowing such facilities to open.

To understand whether SIFs affect overall mortality, researchers used data from two prospective cohort studies of people who inject drugs (PWID) in Vancouver, Canada. Every six months between December 2006 and June 2017, participants responded to a questionnaire asking about sociodemographic information, drug use, use of health interventions such as SIFs and more. They were also asked to provide blood samples for medical testing or monitoring.

Ultimately, the total sample included 811 participants. More than half (432) reported frequent (that is, at least weekly) SIF use at baseline. Over the span of the study period, 112 participants died, corresponding to a crude mortality rate of 22.7 deaths per 1,000 person-years. The leading causes of deaths were non-accidental (which included neoplasms and circulatory disease), ill-defined or unknown, overdose and HIV-related.

After adjusting for several factors, including age, sex, HIV seropositivity, public injection and more, researchers found that “frequent SIF use remained significantly associated with decreased risk of all-cause mortality.”

“Existing modeling and simulation studies indicate that SIFs avert numerous overdose deaths per year,” the study, which was published in the journal PLOS Medicine in late November, states. “Moreover, past research relying on aggregate data has demonstrated the role of SIFs in reducing local population-based rates of fatal overdose. However, we believe that ours is the first study to identify an individual-level association between frequent SIF use and decreased risk of all-cause mortality among a community-recruited cohort of PWID.”

Although researchers did not investigate why there was an association between frequent SIF use and a lower risk of all-cause mortality, they do offer some potential explanations based on existing literature. Studies have shown that supervised consumptions sites are associated with safer syringe use, including a decline in sharing, reusing, outdoor injecting and hurried injecting. Additionally, these facilities are equipped to handle medical emergencies, such as overdose, and are staffed with people trained in addiction treatment.

“Together with the findings of previous research,” the authors write, “our findings underscore the need for continued efforts to enhance access to SIFs as a strategy to reduce mortality among PWID. In particular, given that SIFs have limited geographic coverage and that PWID have been found to often encounter long wait times in accessing SIF services in this setting, the broader expansion of SIFs may serve to improve service accessibility and thereby reduce the potential for mortality and other harms among this population.”

Lead author Mary Clare Kennedy summarized her study results online, tweeting in part: “Our findings add to the large body of scientific evidence demonstrating the critical role of supervised injection facilities in saving lives, reducing harm & promoting health among people who inject drugs.”

“At a time when evidence-based interventions are urgently needed to address the disproportionately high burden of preventable deaths and suffering experienced by people who use drugs, efforts to scale up access to supervised injection facilities should be a public health priority.”

On the presidential campaign trail, entrepreneur Andrew Yang, South Bend, Indiana Mayor Pete Buttigieg, former Housing and Urban Development Secretary Julián Castro, Sen. Elizabeth Warren (D-MA) and Sen. Bernie Sanders (I-VT) have all voiced support for safe consumption sites.

Civil Rights Groups Push To End Criminalization Of Marijuana And Other Drugs

Photo by Jair Lázaro on Unsplash 

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Science & Health

Scientists Uncover ‘Strong Relationship’ Between Psychedelic Use And Connection With Nature

Published

on

People who claim a stronger bond with nature following a psychedelic experience aren’t just blowing smoke, according to new research.

“We found a strong relationship between the amount of lifetime use of psychedelics and nature relatedness, as well as increases in nature relatedness from before to after psychedelic use,” researchers concluded in a study published last month in the International Journal of Environmental Research and Public Health.

To measure how psychedelics influence perspectives on nature, 654 people planning to take substances such as psilocybin mushrooms, LSD, ayahuasca, DMT, mescaline and ibogaine were invited by Imperial College London’s Centre for Psychedelic Research to take part in the online study. Participants were then sent email reminders “at multiple time-points before and after the indicated date of the experience.”

Using statistical analysis, the researchers found that “nature relatedness was significantly increased with two weeks, four weeks and two years after the psychedelic experience” and that participants’ experience boosted feelings of “well-being” when their attitudes toward nature increased.

In other words, psychedelic-induced appreciation for the natural world seems to correspond with psychological health.

“A significant positive association was observed between changes in nature relatedness and changes in psychological well-being,” the authors wrote.

“The here presented evidence…bears relevance for psychedelic treatment models in mental health and, in the face of the current ecological crisis, planetary health.”

Surprisingly, associations with nature were “not only sustained, but rather elevated even further after two years” following the experience. According to the authors, the participants could be experiencing a “positive-feedback-like effect,” where psychedelic use “led individuals to subsequently seek more exposure to nature,” thus reinforcing connections with the natural world.

“These findings point to the potential of psychedelics to induce enduring positive changes in the way humans relate to their natural environments,” the authors wrote.

The research team noted that the sample population’s baseline connection with nature was “substantially higher than demographically similar populations,” but that “may be explained by the psychedelic-experienced nature of the current sample—implying that prior psychedelic use had already caused an increase in nature relatedness.”

“It is an increasingly well-established principle that the quality of an individual’s acute experience under a psychedelic is predictive of subsequent long-term psychological outcomes—such as improvements in mental health.”

According to the researchers, this study is “the first empirical evidence for a causative role of psychedelic use in the enhancement of nature relatedness in a large sample of healthy participants.”

“By meaningfully connecting with nature during a psychedelic experience (especially so if the experience is within the context of pleasing natural surroundings), otherwise healthy individuals may be enticed to spend more time in nature in the future, thereby adopting healthier, more nature-related lifestyles,” the study concluded.

The research results come amid a growing nationwide movement to decriminalize psychedelics across the U.S. following successful campaigns last year to reform laws criminalizing psilocybin in Denver, and those covering a broader array of psychedelics in Oakland.

Decriminalize Nature, the aptly named group that led the Oakland campaign, is now spearheading similar efforts that have extended to nearly 100 other cities. Localities considering decriminalizing psychedelics next include Chicago, Berkeley and Dallas.

A separate group is working to qualify a statewide measure for Oregon’s 2020 ballot that would legalize psilocybin for therapeutic use. Additionally, activists in Portland also began collecting signatures last month for a local measure that would decriminalize a wide range of psychedelics such as mescaline and ayahuasca.

Meanwhile, California activists are aiming to place an initiative on the state’s ballot to legalize psilocybin for adult use.

The psychedelics movement is also reaching the presidential campaign, with Democratic contender Andrew Yang saying last month that he wants to make psilocybin mushrooms “more freely available,” especially for military veterans.

Andrew Yang Says Legalizing ‘Certain Drugs’ Can Hurt Cartels

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!